The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Drug screening in a zebrafish model of Duchenne muscular dystrophy
Open accessAbstract
Two known zebrafish dystrophin mutants, sapje and sapje -like ( sap c/100 ), represent excellent small-animal models of human muscular dystrophy. Using these dystrophin-null zebrafish, we have screened the Prestwick chemical library for small molecules that modulate the muscle phenotype in these fish. With a quick and easy birefringence assay, we have identified seven small molecules that influence muscle pathology in dystrophin-null zebrafish without restoration of dystrophin expression. Three of seven candidate chemicals restored normal birefringence and increased survival of dystrophin-null fish. One chemical, aminophylline, which is known to be a nonselective phosphodiesterase (PDE) inhibitor, had the greatest ability to restore normal muscle structure and up-regulate the cAMP-dependent PKA pathway in treated dystrophin-deficient fish. Moreover, other PDE inhibitors also reduced the percentage of affected sapje fish. The identification of compounds, especially PDE inhibitors, that moderate the muscle phenotype in these dystrophin-null zebrafish validates the screening protocol described here and may lead to candidate molecules to be used as therapeutic interventions in human muscular dystrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins
Chen, A. E., Ginty, D. D., & Fan, C.-M. (2005) · Nature · doi:10.1038/nature03126 · Cited by 309
Cited by
Hooked! Modeling human disease in zebrafish
Santoriello, C., & Zon, L. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60434 · Cited by 513
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
Self-citationSkeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Tabebordbar, M., Wang, E. T., & Wagers, A. J. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132450 · Cited by 79
Zebrafish models of sarcopenia
Daya, A., Donaka, R., & Karasik, D. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.042689 · Cited by 55
The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish.
Winder, S. J., Lipscomb, L., Angela Parkin, C., & Juusola, M. (2011) · PLoS Currents · doi:10.1371/currents.rrn1286 · Cited by 30
“A recent screen from the Kunkel Group has also validated this approach and identified a number of compounds that appear effective in reducing dystrophic symptoms in zebrafish [9] , in particular PDE5 inhibitors appear to be useful in this regard as they have also been shown to be effective in mdx mice [ [10] , [11] ].”
Metadata
- Authors
- Kawahara, G., Karpf, J. A., Myers, J. A., Alexander, M. S., Guyon, J. R., & Kunkel, L. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-03-14
- Volume
- 108
- Issue
- 13
- Pages
- 5331-5336
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1967740895
- Cited by
- 191
- References
- 2
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug screening in a zebrafish model of Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1073/pnas.1102116108
- The paper
- Kawahara, G., Karpf, J. A., Myers, J. A., Alexander, M. S., Guyon, J. R., & Kunkel, L. M. (2011). Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1102116108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.